# US 2017/0362315 A1 · Pan-ELR+ CXC CHEMOKINE ANTIBODIES

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362315 A1
- Document ID: US20170362315A1
- Status: Published application
- Kind: A1
- Application number: 15/695,338
- Filed: 2017-09-05
- Published: 2017-12-21
- Earliest claimed: 2013-03-15
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Catherine Brautigam Beidler; Kristine Kay Kikly; Beth Ann Strifler; Derrick Ryan Witcher
- Web page: https://patentgrep.com/patent/US20170362315A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- C07K 16/244: {Interleukins [IL]}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method of treating cancer in a patient, comprising administering to the patient a therapeutically effective amount of an antibody that binds human growth-regulated oncogene (“Gro”)-alpha, human Gro-beta, human Gro-gamma, human epithelial neutrophil activating peptide-78, human granulocyte chemotactic protein-2, human neutrophil activating protein-2, and human interleukin-8, the antibody comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises light chain complementarity determining regions (“LCDR”) LCDR1, LCDR2, LCDR3 and the HCVR comprises heavy chain complementarity determining regions (“HCDR”) HCDR1, HCDR2, HCDR3, wherein LCDR1 is RASQSISNNLH (SEQ ID NO: 7), LCDR2 is YTSRSVS (SEQ ID NO: 8), LCDR3 is GQNNEWPEV (SEQ ID NO: 9), HCDR1 is GYEFTSYWIH (SEQ ID NO: 10), HCDR2 is NISPNSGSANYNEKFKS (SEQ ID NO: 11), and HCDR3 is EGPYSYYPSRXaaYYGSDL (SEQ ID NO: 20) wherein Xaa is E or Q.

### Claim 20 (depends on 19)

The method of claim 19, wherein the amino acid sequence of the HCVR is SEQ ID NO: 2 or SEQ ID NO: 14 and the amino acid sequence of the LCVR is SEQ ID NO: 4 or 16.

### Claim 21 (depends on 19)

The method of claim 19, wherein the amino acid sequence of the HCVR is SEQ ID NO: 2 and the amino acid sequence of the LCVR is SEQ ID NO: 4.

### Claim 22 (depends on 19)

The method of claim 19, wherein the amino acid sequence of the heavy chain is SEQ ID NO: 1 and the amino acid sequence of the light chain is SEQ ID NO: 3.

### Claim 23 (depends on 19)

The method of claim 19, wherein the antibody comprises two heavy chains having the amino acid sequence of SEQ ID NO: 1, and two light chains having the amino acid sequence of SEQ ID NO: 3.

### Claim 24 (depends on 19)

The method of claim 19, wherein the cancer is one of renal cancer or ovarian cancer.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cancer is one of renal cancer or ovarian cancer.

### Claim 26

A method of treating cancer in a patient, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising an antibody and one or more pharmaceutically acceptable carriers, diluents or excipients, the antibody comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises light chain complementarity determining regions (“LCDR”) LCDR1, LCDR2, LCDR3 and the HCVR comprises heavy chain complementarity determining regions (“HCDR”) HCDR1, HCDR2, HCDR3, wherein LCDR1 is RASQSISNNLH (SEQ ID NO: 7), LCDR2 is YTSRSVS (SEQ ID NO: 8), LCDR3 is GQNNEWPEV (SEQ ID NO: 9), HCDR1 is GYEFTSYWIH (SEQ ID NO: 10), HCDR2 is NISPNSGSANYNEKFKS (SEQ ID NO: 11), and HCDR3 is EGPYSYYPSRXaaYYGSDL (SEQ ID NO: 20) wherein Xaa is E or Q.

### Claim 27 (depends on 26)

The method of claim 26, wherein the amino acid sequence of the HCVR is SEQ ID NO: 2 or SEQ ID NO: 14 and the amino acid sequence of the LCVR is SEQ ID NO: 4 or 16.

### Claim 28 (depends on 26)

The method of claim 26, wherein the amino acid sequence of the HCVR is SEQ ID NO: 2 and the amino acid sequence of the LCVR is SEQ ID NO: 4.

### Claim 29 (depends on 26)

The method of claim 26, wherein the amino acid sequence of the heavy chain is SEQ ID NO: 1 and the amino acid sequence of the light chain is SEQ ID NO: 3.

### Claim 30 (depends on 26)

The method of claim 26, wherein the antibody comprises two heavy chains having the amino acid sequence of SEQ ID NO: 1, and two light chains having the amino acid sequence of SEQ ID NO: 3.

### Claim 31 (depends on 26)

The method of claim 26, wherein the cancer is one of renal cancer or ovarian cancer.

### Claim 32 (depends on 30)

The method of claim 30, wherein the cancer is one of renal cancer or ovarian cancer.
